News articles about Pluristem Therapeutics (NASDAQ:PSTI) have trended somewhat negative recently, according to AlphaOne. The research group, a subsidiary of Accern, identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a media sentiment score of -0.12 on AlphaOne’s scale. AlphaOne also gave media coverage about the biotechnology company an impact score of 50 out of 100, meaning that recent media coverage is somewhat likely to have an effect on the stock’s share price in the immediate future.
Pluristem Therapeutics (NASDAQ:PSTI) traded up 2.92% on Friday, hitting $1.41. 547,885 shares of the stock traded hands. The stock’s market cap is $135.45 million. Pluristem Therapeutics has a 12-month low of $1.04 and a 12-month high of $1.85. The stock has a 50-day moving average price of $1.28 and a 200 day moving average price of $1.38.
Several brokerages have commented on PSTI. Zacks Investment Research lowered shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, April 13th. Maxim Group lowered shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 13th. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the company a “buy” rating in a report on Saturday, February 11th. Finally, FBR & Co reiterated a “buy” rating on shares of Pluristem Therapeutics in a report on Tuesday, January 10th.
ILLEGAL ACTIVITY WARNING: “Pluristem Therapeutics (PSTI) Earning Somewhat Negative Media Coverage, AlphaOne Reports” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/04/21/pluristem-therapeutics-psti-earning-somewhat-negative-media-coverage-alphaone-reports.html.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.